Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by SpringWorks Therapeutics, Inc.

< Previous 1 2 Next >
SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
SpringWorks Therapeutics to Present at Upcoming Investor Conferences
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
SpringWorks Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
SpringWorks Therapeutics Highlights 2023 Accomplishments and Anticipated Milestones for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
SpringWorks Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
SpringWorks Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
SpringWorks Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
SpringWorks Therapeutics Announces Proposed Public Offering of Common Stock
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
SpringWorks Therapeutics to Participate in the 6th Annual Evercore ISI HealthCONx Conference
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
SpringWorks Therapeutics Announces FDA Approval of OGSIVEO™ (nirogacestat) as the First and Only Treatment for Adults with Desmoid Tumors
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
SpringWorks Therapeutics Announces Positive Topline Results from the Phase 2b ReNeu Trial of Mirdametinib in NF1-PN
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
SpringWorks Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
SpringWorks Therapeutics Announces Presentation of Additional Data from Phase 3 DeFi Trial of Nirogacestat in Adults with Desmoid Tumors at the 2023 CTOS Annual Meeting
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
SpringWorks Therapeutics Appoints Dr. Tai-An Lin as Chief Scientific Officer
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
SpringWorks Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
SpringWorks Therapeutics to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
SpringWorks Therapeutics Announces PDUFA Date Extension for Nirogacestat NDA
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
SpringWorks Therapeutics Announces Full Enrollment of Phase 2 Trial Evaluating Nirogacestat in Patients with Ovarian Granulosa Cell Tumors
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
SpringWorks Therapeutics Announces Presentation of Additional Data from Phase 3 DeFi Trial of Nirogacestat in Adults with Desmoid Tumors at the 2023 ASCO Annual Meeting
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
SpringWorks Therapeutics to Participate in the TD Cowen 4th Annual Oncology Innovation Summit
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
SpringWorks Therapeutics Announces Clinical Data Presentations of Nirogacestat in Combination with BCMA-Directed Therapies at the European Hematology Association 2023 Congress
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers GSK SWTX
SpringWorks Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
SpringWorks Therapeutics to Participate in the Bank of America Securities 2023 Health Care Conference
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
SpringWorks and BeiGene Present Clinical Data on Lifirafenib, in combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Association for Cancer Research Annual Meeting 2023
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers BGNE SWTX
MapKure, SpringWorks and BeiGene Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors at the American Association for Cancer Research Annual Meeting 2023
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers BGNE SWTX
SpringWorks Therapeutics Announces New England Journal of Medicine Publication of Phase 3 DeFi Trial Evaluating Nirogacestat in Adults with Desmoid Tumors
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
SpringWorks Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.